Intarcia secures additional $206 million funding

30 December 2016

Privately-held US biotech firm Intarcia Therapeutics says it has completed its second major close of the Series EE equity financing, and also entered into a relationship with the Bill & Melinda Gates Foundation to help prevent the spread of HIV in Sub-Saharan Africa and other countries where the HIV epidemic is most severe.

Following the initial Series EE equity financing in September, Intarcia secures an additional $206 million in the second close of the Series EE equity financing. A third and final close is planned in first-quarter 2017.

Deal with Gates Foundation to develop HIV prophylactic

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK